Allan Lawrie

List of Publications by Year in Descending Order

120 papers	4,302 citations	38 h-index	63 g-index
164 ext. papers	5,499 ext. citations	8.9 avg, IF	5.18 L-index

#	Paper	IF	Citations
120	Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 797561	5.4	1
119	Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements.. *Journal of Cardiovascular Magnetic Resonance*, **2022**, 24, 25	6.9	1
118	The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.. *Circulation Research*, **2022**, 130, 1466-1486	15.7	2
117	Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 430-445	9.4	8
116	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. *Nature Communications*, **2021**, 12, 7104	17.4	1
115	Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. *European Respiratory Journal*, **2021**, 57,	13.6	12
114	A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 236-245	4.1	20
113	Zebrafish as a tractable model of human cardiovascular disease. *British Journal of Pharmacology*, **2021**,	8.6	14
112	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. *Genome Medicine*, **2021**, 13, 80	14.4	11
111	Frataxin and endothelial cell senescence in pulmonary hypertension. *Journal of Clinical Investigation* , **2021**, 131,	15.9	2
110	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. *EBioMedicine*, **2021**, 69, 103444	8.8	5
109	Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. *JACC: Cardiovascular Imaging*, **2021**, 14, 1271-1272	8.4	3
108	Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension. *Annals of the American Thoracic Society*, **2021**, 18, 34-43	4.7	1
107	The role of chemokines and chemokine receptors in pulmonary arterial hypertension. *British Journal of Pharmacology*, **2021**, 178, 72-89	8.6	23
106	Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. *Thorax*, **2021**, 76, 1032-1035	7.3	2
105	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 586-594	10.2	14
104	Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 575-585	10.2	46

103	Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 458-468	10.2	37
102	A toolbox for the longitudinal assessment of healthspan in aging mice. *Nature Protocols*, **2020**, 15, 540-574	13.8	38
101	Loss of Endothelial Endoglin Promotes High-Output Heart Failure Through Peripheral Arteriovenous Shunting Driven by VEGF Signaling. *Circulation Research*, **2020**, 126, 243-257	15.7	21
100	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. *Circulation*, **2020**, 142, 1464-1484	16.7	46
99	Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. *Circulation Genomic and Precision Medicine*, **2020**,	5.2	9
98	Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. *European Respiratory Journal*, **2020**, 56,	13.6	1
97	Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. *Circulation Research*, **2019**, 124, 904-919	15.7	81
96	Germline selection shapes human mitochondrial DNA diversity. *Science*, **2019**, 364,	33.3	105
95	The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry. *Pulmonary Circulation*, **2019**, 9, 2045894019848649	2.7	4
94	Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. *American Journal of Human Genetics*, **2019**, 104, 948-956	11	17
93	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. *European Respiratory Journal*, **2019**, 53,	13.6	17
92	Repeatability and Sensitivity to change of right ventricular analysis methods using cardiac magnetic resonance imaging in PAH: results from the RESPIRE Study **2019**,		2
91	A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. *Nature Communications*, **2019**, 10, 5183	17.4	12
90	Screening strategies for pulmonary arterial hypertension. *European Heart Journal Supplements*, **2019**, 21, K9-K20	1.5	16
89	Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. *Pulmonary Circulation*, **2019**, 9, 2045894019890549	2.7	13
88	Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 199-210	10.2	39
87	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238	35.1	55
86	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. *Nature Communications*, **2018**, 9, 1416	17.4	182

85	Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. *Scientific Reports*, **2018**, 8, 1300	4.9	33
84	Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications. *Circulation*, **2018**, 138, 287-304	16.7	62
83	Selective improvement of pulmonary arterial hypertension with a dual ET/ET receptors antagonist in the apolipoprotein E model of PAH and atherosclerosis. *Pulmonary Circulation*, **2018**, 8, 2045893217752328	2.7	8
82	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. *BMC Pulmonary Medicine*, **2018**, 18, 41	3.5	31
81	Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. *Frontiers in Medicine*, **2018**, 5, 172	4.9	3
80	Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data. *Frontiers in Medicine*, **2018**, 5, 175	4.9	9
79	The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2018**, 52,	13.6	41
78	Divergent Roles for TRAIL in Lung Diseases. *Frontiers in Medicine*, **2018**, 5, 212	4.9	16
77	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. *American Journal of Human Genetics*, **2018**, 103, 3-18	11	27
76	Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002087	5.2	33
75	The Hepcidin/Ferroportin axis modulates proliferation of pulmonary artery smooth muscle cells. *Scientific Reports*, **2018**, 8, 12972	4.9	19
74	High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project. *Pulmonary Circulation*, **2018**, 8, 2045894018798613	2.7	12
73	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. *American Journal of Human Genetics*, **2018**, 103, 144-153	11	18
72	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. *American Journal of Human Genetics*, **2017**, 100, 334-342	11	14
71	Hypoxia determines survival outcomes of bacterial infection through HIF-1alpha dependent re-programming of leukocyte metabolism. *Science Immunology*, **2017**, 2,	28	45
70	Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2017**, 36, 871-879	5.8	13
69	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 717-726	35.1	62
68	Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 228-239	10.2	79

67	Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1478-1481	10.2	1
66	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *American Journal of Human Genetics*, **2017**, 100, 75-90	11	235
65	Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. *Experimental Physiology*, **2017**, 102, 180-189	2.4	14
64	Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. *Trends in Molecular Medicine*, **2017**, 23, 31-45	11.5	108
63	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. *Circulation*, **2017**, 136, 2022-2033	16.7	75
62	Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. *Pulmonary Circulation*, **2017**, 7, 768-776	2.7	18
61	From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease. *Pharmacology & Therapeutics*, **2017**, 169, 78-82	13.9	6
60	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. *Circulation*, **2017**, 135, 460-475	16.7	96
59	156 Inducers of pulmonary arterial hypertension upregulate the expression of plasma membrane calcium atpase 1 in pulmonary artery smooth muscle cells. *Heart*, **2017**, 103, A113.1-A113	5.1	
58	Specific Alleles of CLN7/MFSD8, a Protein That Localizes to Photoreceptor Synaptic Terminals, Cause a Spectrum of Nonsyndromic Retinal Dystrophy **2017**, 58, 2906-2914		24
57	S107 Genotype-phenotype associations in pulmonary arterial hypertension caused by BMPR2 and EIF2AK4 variants. *Thorax*, **2016**, 71, A63-A64	7.3	
56	MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. *Journal of Clinical Investigation*, **2016**, 126, 2495-508	15.9	96
55	S85 Reduction of CD68 macrophages causes gender specific spontaneous pulmonary arterial hypertension in mice. *Thorax*, **2016**, 71, A49.1-A49	7.3	
54	S87 Deficiency of toll-like receptor 3 (TLR3) exacerbates pulmonary hypertension in mice. *Thorax*, **2016**, 71, A50.1-A50	7.3	
53	S104 Hypoxia preconditions the innate immune response to acute bacterial pulmonary infections. *Thorax*, **2016**, 71, A61.2-A62	7.3	
52	Heart rate reduction with ivabradine promotes shear stress-dependent anti-inflammatory mechanisms in arteries. *Thrombosis and Haemostasis*, **2016**, 116, 181-90	7	16
51	E microRNA-140-5p and SMURF1 Regulate Pulmonary Arterial Hypertension. *Heart*, **2016**, 102, A147-A147	5.1	1
50	Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1514-1516	13.6	29

49	P245 Whole blood levels of microrna-34a predict survival and regulate genes associated with pulmonary arterial hypertension. *Thorax*, **2016**, 71, A220.2-A221	7.3	1
48	T5 MicroRNA-140-5p Regulates Disease Phenotype in Experimental Pulmonary Arterial Hypertension via SMURF1. *Thorax*, **2015**, 70, A3.1-A3	7.3	2
47	Osteoprotegerin in Cardiometabolic Disorders. *International Journal of Endocrinology*, **2015**, 2015, 564934	2.7	54
46	S3 Reduced BMPR2 expression potentiates a pulmonary artery smooth muscle cell specific IL-1 response. *Thorax*, **2015**, 70, A5.3-A6	7.3	
45	Elevated plasma CXCL12 is associated with a poorer prognosis in pulmonary arterial hypertension. *PLoS ONE*, **2015**, 10, e0123709	3.7	19
44	Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. *Circulation: Cardiovascular Interventions*, **2015**, 8, e002569	6	46
43	Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 254-7	10.2	86
42	Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. *JACC: Cardiovascular Interventions*, **2015**, 8, 2013-2023	5	42
41	183 Novel OPG Protein Interactions Regulate Survival, Proliferation And Pah-associated Gene Expression in Pulmonary Arterial Smooth Muscle Cells. *Heart*, **2014**, 100, A102.3-A103	5.1	
40	Influence of pre-analytical and analytical factors on osteoprotegerin measurements. *Clinical Biochemistry*, **2014**, 47, 1279-85	3.5	7
39	T5 Opg Regulates Pulmonary Arterial Smooth Muscle Cell Proliferation And The Expression Of Pah-associated Genes Via Fas. *Thorax*, **2014**, 69, A2-A3	7.3	1
38	TRAIL Deficient Mice Are Protected from Sugen/Hypoxia Induced Pulmonary Arterial Hypertension. *Diseases (Basel, Switzerland)*, **2014**, 2, 260-273	4.4	3
37	A report on the use of animal models and phenotyping methods in pulmonary hypertension research. *Pulmonary Circulation*, **2014**, 4, 2-9	2.7	11
36	MicroRNA in pulmonary vascular disease. *Progress in Molecular Biology and Translational Science*, **2014**, 124, 43-63	4	10
35	The role of the osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension. *Vascular Pharmacology*, **2014**, 63, 114-7	5.9	4
34	Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 294-302	10.2	126
33	Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling. *Cardiovascular Research*, **2013**, 100, 252-61	9.9	41
32	Pulmonary hypertension in COPD: results from the ASPIRE registry. *European Respiratory Journal*, **2013**, 41, 1292-301	13.6	117

31	P157 Hepatocyte growth factor concentration correlates with haemodynamic severity in connective tissue disease-associated pulmonary arterial hypertension. *Thorax*, **2013**, 68, A146.2-A147	7.3	
30	No evidence for cardiac dysfunction in Kif6 mutant mice. *PLoS ONE*, **2013**, 8, e54636	3.7	6
29	Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis. *Thorax*, **2012**, 67, 796-803	7.3	25
28	Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. *Pulmonary Circulation*, **2012**, 2, 21-7	2.7	20
27	ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. *European Respiratory Journal*, **2012**, 39, 945-55	13.6	260
26	Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. *Journal of Experimental Medicine*, **2012**, 209, 1919-35	16.6	67
25	03 Tissue Trail Drives Pulmonary Vascular Remodeling and its Inhibition Reverses Experimental Pulmonary Arterial Hypertension. *Heart*, **2012**, 98, A1.3-A1	5.1	
24	Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. *American Journal of Pathology*, **2011**, 179, 1693-705	5.8	47
23	TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. *Journal of Leukocyte Biology*, **2011**, 90, 855-65	6.5	103
22	14 The role of TILRR in vascular cell inflammation and development of atherosclerosis. *Heart*, **2011**, 97, e7-e7	5.1	
21	T6 TRAIL is a potential novel therapeutic target in pulmonary arterial hypertension. *Thorax*, **2011**, 66, A3-A3	7.3	
20	P5 Pulmonary hypertension in a mouse model with reduced macrophage number (MacLow). *Thorax*, **2011**, 66, A68-A69	7.3	
19	S69 Serum osteoprotegerin predicts mortality in a prospective study on incident cases of pulmonary arterial hypertension. *Thorax*, **2011**, 66, A34-A34	7.3	
18	S111 The role of TNF-related apoptosis inducing ligand (TRAIL) in pulmonary fibrosis. *Thorax*, **2011**, 66, A51-A52	7.3	1
17	S151 TRAIL deficiency is protective in experimental pulmonary arterial hypertension. *Thorax*, **2010**, 65, A68-A68	7.3	
16	P34 Characterising T cell sub-populations in pulmonary hypertension. *Thorax*, **2010**, 65, A91-A91	7.3	
15	S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4. *Circulation Research*, **2009**, 105, 639-47, 13 p following 647	15.7	69
14	Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. *American Journal of Pathology*, **2008**, 172, 256-64	5.8	65

13	Hypoxia down-regulates cyclic guanidine monophosphate-dependent protein kinase in fetal pulmonary vascular smooth muscle cell through generation of reactive oxygen species and promotes development of pulmonary hypertension. *Chest*, **2005**, 128, 577S-578S	5.3	11
12	Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell migration through multiple signaling pathways. *Chest*, **2005**, 128, 577S	5.3	11
11	VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection. *Journal of Gene Medicine*, **2005**, 7, 375-85	3.5	3
10	Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. *Gene Therapy*, **2005**, 12, 1154-7	4	48
9	Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. *Circulation Research*, **2005**, 97, 227-35	15.7	135
8	Apolipoprotein D and platelet-derived growth factor-BB synergism mediates vascular smooth muscle cell migration. *Circulation Research*, **2004**, 95, 179-86	15.7	29
7	Apolipoprotein D inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferated by preventing translocation of phosphorylated extracellular signal regulated kinase 1/2 to the nucleus. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 2172-7	9.4	46
6	Ultrasound-enhanced transgene expression in vascular cells is not dependent upon cavitation-induced free radicals. *Ultrasound in Medicine and Biology*, **2003**, 29, 1453-61	3.5	54
5	Ultrasound gene therapy: on the road from concept to reality. *Echocardiography*, **2001**, 18, 339-47	1.5	139
4	Microbubble-enhanced ultrasound for vascular gene delivery. *Gene Therapy*, **2000**, 7, 2023-7	4	303
3	Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. *Circulation*, **1999**, 99, 2617-20	16.7	169
2	Bayesian inference associates rare KDR variants with specific phenotypes in pulmonary arterial hypertension		3
1	Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH		4